BARD1 Life Sciences Ltd (ASX Code: BD1)

Recommendation: Strong Buy (Speculative) at A$0.027 per share

Market Capitalisation: 552 m shares @ A$0.027 per share = just A$14.0M

Target Price (Preliminary) – Our preliminary target price is A$0.09 – based on a targeted A$50M mkt cap.

BD1 is developing a biomarker for early detection of lung cancer

by way of a standard blood test.

State One believes that Bard1 has the potential to enjoy a significant rise in its share price over the next six months. This will be achieved, firstly by having the US-based Meso-Scale independently validate and optimise the initial tests results already obtained by Dr Irminger and her team at the UNIGE lab; and secondly by increasing the sample size three fold after the delivery of an additional 450 blood samples. During this six month period it is expected that Dr Irminger’s scientific paper should also be reviewed and published in the scientific world.